findmyKOL
Clinical trialNCT07465276RecruitingPhase 2Interventional

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

SponsorDana-Farber Cancer InstituteEnrollment32Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Glenn Hanna →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ficerafusp alfaPembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Mar 2026
Primary completion
30 Apr 2028
Completion
30 Apr 2030
Last update posted
27 Mar 2026
Registered enrollment
32
Registry id
NCT07465276
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.